ES2525759T3 - Medios y métodos para inmunoterapia celular activa de cáncer usando células tumorales destruidas por alta presión hidrostática y células dendríticas - Google Patents

Medios y métodos para inmunoterapia celular activa de cáncer usando células tumorales destruidas por alta presión hidrostática y células dendríticas Download PDF

Info

Publication number
ES2525759T3
ES2525759T3 ES12734884.5T ES12734884T ES2525759T3 ES 2525759 T3 ES2525759 T3 ES 2525759T3 ES 12734884 T ES12734884 T ES 12734884T ES 2525759 T3 ES2525759 T3 ES 2525759T3
Authority
ES
Spain
Prior art keywords
hydrostatic pressure
tumor cells
cancer
methods
high hydrostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12734884.5T
Other languages
English (en)
Inventor
Jirina Bartunková
Radek Spísek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sotio AS
Original Assignee
Sotio AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio AS filed Critical Sotio AS
Application granted granted Critical
Publication of ES2525759T3 publication Critical patent/ES2525759T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica para inducir una respuesta inmunitaria contra células tumorales que comprende a) células tumorales que son apoptóticas provocado por el tratamiento con alta presión hidrostática igual a o mayor de 100 MPa durante 10 minutos a 2 horas y b) células dendríticas

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
ES12734884.5T 2011-07-05 2012-07-04 Medios y métodos para inmunoterapia celular activa de cáncer usando células tumorales destruidas por alta presión hidrostática y células dendríticas Active ES2525759T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161504387P 2011-07-05 2011-07-05
EP11172622A EP2543386A1 (en) 2011-07-05 2011-07-05 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
US201161504387P 2011-07-05
EP11172622 2011-07-05
PCT/EP2012/062950 WO2013004708A1 (en) 2011-07-05 2012-07-04 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Publications (1)

Publication Number Publication Date
ES2525759T3 true ES2525759T3 (es) 2014-12-30

Family

ID=44359435

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12734884.5T Active ES2525759T3 (es) 2011-07-05 2012-07-04 Medios y métodos para inmunoterapia celular activa de cáncer usando células tumorales destruidas por alta presión hidrostática y células dendríticas

Country Status (20)

Country Link
US (1) US20140086957A1 (es)
EP (2) EP2543386A1 (es)
JP (1) JP5986196B2 (es)
KR (1) KR102035873B1 (es)
CN (3) CN109125347A (es)
AU (2) AU2012280322B2 (es)
BR (2) BR112013031084B1 (es)
CA (1) CA2833946A1 (es)
DK (1) DK2691110T3 (es)
EA (1) EA030061B1 (es)
ES (1) ES2525759T3 (es)
PL (1) PL2691110T3 (es)
PT (1) PT2691110E (es)
RS (1) RS53713B1 (es)
RU (1) RU2012127685A (es)
SG (1) SG194201A1 (es)
SI (1) SI2691110T1 (es)
SM (1) SMT201400188B (es)
UA (1) UA111738C2 (es)
WO (1) WO2013004708A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011438A1 (en) 2011-07-05 2013-01-10 SOTIO a.s. Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
CN104258384B (zh) * 2014-09-29 2017-05-03 北京时合生物科技有限公司 一种基于树突状细胞的特异性肿瘤疫苗的制备方法
CN107921063A (zh) * 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN106244543A (zh) * 2016-07-29 2016-12-21 北京时合生物科技有限公司 一种pbmc体外诱导分化成为树突状细胞的方法
JP2020507616A (ja) * 2017-02-17 2020-03-12 アイビタ バイオメディカル インコーポレイテッド 改変された腫瘍細胞および改変された樹状細胞を使用して、腫瘍免疫原性を増強する方法および自己癌免疫療法製品の組成物
CN109810946B (zh) * 2017-11-21 2023-11-21 中国科学院上海药物研究所 天花粉蛋白用于致敏和/激活树突状细胞中的应用
KR20200116112A (ko) * 2018-01-25 2020-10-08 소티오 에이.에스. 화학요법에 순차적인 수지상 세포 백신접종
CA3087823A1 (en) 2018-01-25 2019-08-01 SOTIO a.s. Dendritic cell vaccination in parallel to chemotherapy
WO2020187975A1 (en) 2019-03-19 2020-09-24 SOTIO a.s. Patient selection for treatment with dendritic cell vaccination
JP7340240B2 (ja) * 2019-08-26 2023-09-07 学校法人関西医科大学 細胞又は組織にアポトーシスを誘導する方法
WO2022171792A1 (en) 2021-02-12 2022-08-18 Sctbio A.S. Patient selection for treatment with dendritic cell vaccination
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
CN114807229A (zh) * 2022-05-27 2022-07-29 中国科学院长春应用化学研究所 细胞膜、纳米疫苗及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602709B1 (en) * 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
WO2006047515A2 (en) 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
KR100647847B1 (ko) * 2005-05-27 2006-11-23 크레아젠 주식회사 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법

Also Published As

Publication number Publication date
EA030061B1 (ru) 2018-06-29
BR122019026627B1 (pt) 2021-01-12
PT2691110E (pt) 2014-12-22
SMT201400188B (it) 2015-03-05
NZ618000A (en) 2014-12-24
US20140086957A1 (en) 2014-03-27
KR102035873B1 (ko) 2019-10-23
KR20140040734A (ko) 2014-04-03
CN103648524B (zh) 2016-08-17
EP2691110B1 (en) 2014-10-29
BR112013031084A2 (pt) 2016-11-29
CA2833946A1 (en) 2013-01-10
EA201301089A1 (ru) 2014-05-30
EP2691110A1 (en) 2014-02-05
WO2013004708A1 (en) 2013-01-10
PL2691110T3 (pl) 2015-03-31
DK2691110T3 (en) 2014-11-17
EP2543386A1 (en) 2013-01-09
BR112013031084B1 (pt) 2021-01-12
JP5986196B2 (ja) 2016-09-06
SI2691110T1 (sl) 2015-01-30
CN109125347A (zh) 2019-01-04
CN103648524A (zh) 2014-03-19
CN102861103A (zh) 2013-01-09
RS53713B1 (en) 2015-04-30
AU2016234915B2 (en) 2017-08-31
RU2012127685A (ru) 2014-01-20
UA111738C2 (uk) 2016-06-10
JP2014520780A (ja) 2014-08-25
AU2012280322B2 (en) 2016-07-21
AU2016234915A1 (en) 2016-10-20
SG194201A1 (en) 2013-11-29

Similar Documents

Publication Publication Date Title
ES2525759T3 (es) Medios y métodos para inmunoterapia celular activa de cáncer usando células tumorales destruidas por alta presión hidrostática y células dendríticas
CU20200089A7 (es) Moléculas de unión contra bcma
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
ES2661582T3 (es) Efecto antiinflamatorio de la celulosa microfibrilada
CL2015001983A1 (es) Modulador del receptor de andrógeno y usos de este.
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
AR087380A1 (es) Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
GT201500051A (es) Inhibidores de glucosilceramida sintasa
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
BR112013018534A2 (pt) marcadores de mri, sistemas de entrega e extração e métodos de fabricação e uso dos mesmos
BR112016000561A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
AR120138A1 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
AR100666A1 (es) Criopreservación de células cancerosas apoptóticas para utilizar en la inmunoterapia contra el cáncer, composición farmacéutica, kit
CL2013003282A1 (es) Composicion farmaceutica que comprende celulas tumorales que son apoptoticas a causa de tratamiento con presion hidrostatica y celulas dendriticas; metodo de preparacion; y su uso para tratar cancer.
ES2659519T3 (es) Método para producir medicamentos para combatir tumores
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
AR083117A1 (es) Peptidos del veneno de escorpion rhopalurus junceus y composicion farmaceutica
ES2525833T3 (es) Supresión del crecimiento del cáncer y la metástasis mediante el uso de derivados de ácido nordihidroguayarético con 7-hidroxiestaurosporina
CL2018001138A1 (es) Un método ex vivo para probar la respuesta celular de las poblaciones de células primarias a una droga o combinación de drogas
EP4233536A3 (en) Method for enhancing tumor growth
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo